Relypsa launches new hyperkalemia med Veltassa; Samsung aims for CMO dominance;

@FiercePharma: Gene-testing business boosts Neogen's sales but earnings fall short of high expectations. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: WuXi clarifies just what AstraZeneca is buying, or actually what it isn't buying. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

> Relypsa's ($RLYP) new hyperkalemia treatment Veltassa rolled onto the U.S. market Monday; it won FDA approval in October. Release

> Samsung's heir apparent appeared at a groundbreaking for a new biologics manufacturing plant Monday, underscoring the company's big bet on biopharma. Report

> Chinese drugmaker Shanghai Fosun Pharma's biotech unit plans an IPO in Hong Kong. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Philips' Volcano to keep Sacramento site despite 60 manufacturing layoffs. Article | Follow @FierceMedDev

@EmilyWFierce: Hey doc, what's on the menu when pharma comes calling? Hint: It's not health food. Story from FiercePharmaMarketing | Follow @EmilyWFierce

> DOJ settles with 32 hospitals for $105M over improper Medicare billing related to spinal surgery. Article

> Regulators probe complaints from former Theranos employees over lab, testing practices: WSJ. More

Biotech News

@FierceBiotech: As trouble mounts, a chastened Martin Shkreli says bad boy persona was just an 'experiment.' Article | Follow @FierceBiotech

@JohnCFierce: Boehringer grabs 'breakthrough,' plots pivotal trials for rival to AstraZeneca, Clovis. (What breakthrough?) More | Follow @JohnCFierce

> Eli Lilly taps Halozyme in an $825M delivery deal. News

> Amgen buys another cancer-fighting virus project in a $10.5M deal. Report

Pharma Marketing News

> New FDA policy gives its staff wide latitude on social media. Could pharma freedom follow? More

> Hey doc, what's on the menu when pharma comes calling? Hint: It's not health food. Story

> Bayer, coveting top spots in animal and consumer health, may eye deals for Zoetis, Pfizer OTC. Item

> Headaches for Reckitt over charges of misleading claims for OTC painkillers. Article

Animal Health News

> Sanofi, Boehringer to create new animal health giant in $12.5B asset swap. News

> U.S. states lift bird-flu bans and quarantines as reports of virus mount overseas. Article

> Jaguar shares jump on string of positive news in equine health. Report

> AB Science's Kinavet cancer drug for dogs loses FDA marketing authorization. Item

> Toxin from sea algae impacts memory, behavior in California sea lions: Study. More

Biotech IT News

> Shkreli's Twitter account hacked, spokesperson says. Item

> UCB taps Congenica tech for help with target discovery. News

> MorphoSys picks Dotmatics tool to visualize, analyze screening data. Report

> FDA hits tight timeline for start of precisionFDA open beta. More

> FDA CTO admits security shortcomings are holding back data sharing. Article

And Finally... Proton-pump inhibitors, routinely prescribed to hospitalized patients, may raise the risk of death. More

Suggested Articles

AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

Kinase inhibitors to treat cancer have driven nearly $100 billion in deals since 2010, a trend that's likely to grow, SVB Leerink analysts predict.